^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

LPAR3 overexpression

i
Other names: LPAR3, Lysophosphatidic Acid Receptor 3, LPA3, RP4-678I3, HOFNH30, LP-A3, Edg-7, EDG7, Endothelial Differentiation, Lysophosphatidic Acid G-Protein-Coupled Receptor, 7, Lysophosphatidic Acid Receptor Edg-7, LPA Receptor 3, LPA-3, Calcium-Mobilizing Lysophosphatidic Acid Receptor LP-A3, Endothelial Cell Differentiation Gene 7, LPA Receptor EDG7, GPCR
Entrez ID:
almost3years
Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs. (PubMed, Sci Rep)
PCa cell-platelet interactions reciprocally promoted PCa cell invasion and apoptotic resistance, and these events were insensitive to androgen receptor blockade by bicalutamide...Of participating signaling partners, FN1 and LPAR3 overexpression was observed in PCa specimens compared to normal prostate, while high expression of CCR1 (CCL3L1 receptor), EPHA1 and LPAR5 in PCa was associated with poor patient survival. These findings emphasize that non-overlapping receptor-ligand pairs participate in oncogenesis and thrombosis, highlighting the complexity of any contemplated clinical intervention strategy.
Journal
|
AR (Androgen receptor) • FN1 (Fibronectin 1) • IL32 (Interleukin 32) • LPAR3 (Lysophosphatidic Acid Receptor 3) • CCR1 (C-C Motif Chemokine Receptor 1) • CD55 (CD55 Molecule) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
|
LPAR3 overexpression
|
bicalutamide
almost4years
LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer. (PubMed, Med Oncol)
Our studies further confirmed the LPA3/Gi/MAPKs/NF-κB signals were involved in LPA-induced oncogenic actions in ovarian cancer cells. Our findings indicated that the LPA3 might be a novel precise therapeutic target and potential biomarker for ovarian cancer.
Journal
|
LPAR3 (Lysophosphatidic Acid Receptor 3)
|
LPAR3 overexpression